EHA 2019 | MRD detection with NGS for AML: a new era of diagnostics

Name: MRD detection with NGS for AML: a new era of diagnostics
Uploaded: 2019-06-19T16:30:47.000Z
Duration: 2 min
Description: Torsten Haferlach, MD, from the Munich Leukemia Laboratory, Munich, Germany, sheds light on a potential of a new era in diagnostics with the use of next-generation sequencing (NGS) for detecting measurable residual disease (MRD) status. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Torsten Haferlach • 19 Jun 2019

EHA 2019

Acute Myeloid Leukemia Leukemia

Torsten Haferlach, MD, from the Munich Leukemia Laboratory, Munich, Germany, sheds light on a potential of a new era in diagnostics with the use of next-generation sequencing (NGS) for detecting measurable residual disease (MRD) status. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.